Further details:

Boris Hinz is University of Toronto Distinguished Professor in Tissue Repair and Regeneration with primary appointment in the Faculty of Dentistry, Matrix Dynamics Group. He is cross-appointed with the Faculty of Medicine, Department of Surgery and the Institute of Biomaterials and Biomedical Engineering. Dr. Hinz holds a PhD degree in Cell Biology and Theoretical Biology from the University of Bonn, Germany, obtained in 1998. From 1999 to 2002, he was postdoctoral fellow of Dr. Giulio Gabbiani, Department of Experimental Pathology, University of Geneva, Switzerland. Dr. Hinz then moved on to lead a research group at the Ecole Polytechnique Fédérale de Lausanne (EPFL), Switzerland, joining Cell Biology, Biophysics, and Bioengineering. He was nominated Maître d’enseignement et de recherche (Assistant Professor level) in 2006 and moved to Toronto in 2009. He has been president and is board member of the European Tissue Repair Society, Secretary and inaugural board member of the Canadian Connective Tissue Society, board member of the Wound Healing Society, the International Dupuytren Society and the Canadian Dupuytren Society, Senior Editor of the Journal Wound Repair and Regeneration, and Associate Member of the Faculty of 1000.

Dr. Hinz aims in understanding the role of contractile myofibroblasts in physiological tissue repair and in causing pathological tissue fibrosis. The findings of his lab are published in peer-reviewed journals, including Cell, Nat. Mater., Nat. Med., Curr. Biol., J. Cell Biol., Stem Cells, Cell Reports, Stem Cell Reports, J. Clin. Invest., Nature Immunol., EMBO J., Mol. Biol. Cell, Cardiovascular Res., J. Cell Sci., Biomaterials, Biophys. J., Am. J. Pathol., PLoS One, and the J. Invest. Dermatol., receiving over 10,200 citations by March 2017 with an h-factor of 40 (Scopus). He published 98 peer reviewed articles, 13 book chapters, was invited to >216 seminar and conference talks with >390 congress abstracts. His research led to the creation of two startup companies specialized on anti-fibrotic coatings for silicone implants and novel “soft” cell culture devices. Dr. Hinz’ research is currently funded by multiple grants from the Canadian Institutes of Health Research (CIHR), Natural Sciences and Engineering Research Council of Canada (NSERC), Canada Foundation for Innovation (CFI), Ontario Research Foundation (ORF), the Connaught Innovation Program, and the European Union’s Transnational Program for Projects on Rare Diseases.